Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Data derived from: D ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The use of SGLT2 inhibitors and GLP-1 receptor agonists ...

Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, first-in-class small molecule drugs that inhibit hypoxia-inducible factors 1 ...

When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...

Use of sodium–glucose cotransporter-2 (SGLT-2) inhibitors rather than metformin as first-line treatment for type 2 diabetes appears to cut the risk for heart failure hospitalization but not myocardial ...

Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...

SGLT-2 inhibitor use, compared with DPP-4 inhibitor use, was associated with a lower incidence of epilepsy among patients with type 2 diabetes. The use of sodium-glucose cotransporter 2 (SGLT-2) ...

The study covered in this summary is under consideration at Cardiovascular Diabetology and was published on researchsquare.com as a preprint and has not yet been peer reviewed. Patients with type 2 ...